Shares of Palatin Technologies, Inc. (NYSEAMERICAN:PTN) gapped up prior to trading on Thursday . The stock had previously closed at $0.77, but opened at $0.84. Palatin Technologies shares last traded at $0.93, with a volume of 4078400 shares trading hands.
A number of analysts have weighed in on the company. Canaccord Genuity set a $6.00 target price on Palatin Technologies and gave the stock a “buy” rating in a report on Monday, November 13th. Zacks Investment Research lowered Palatin Technologies from a “buy” rating to a “hold” rating in a report on Saturday, October 7th. Finally, Roth Capital set a $2.00 target price on Palatin Technologies and gave the stock a “buy” rating in a report on Sunday, October 29th.
The company has a market capitalization of $163.46, a price-to-earnings ratio of 18.80 and a beta of 1.67.
An institutional investor recently raised its position in Palatin Technologies stock. Bank of New York Mellon Corp boosted its stake in shares of Palatin Technologies, Inc. (NYSEAMERICAN:PTN) by 500.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 151,473 shares of the biopharmaceutical company’s stock after buying an additional 126,236 shares during the period. Bank of New York Mellon Corp owned 0.08% of Palatin Technologies worth $101,000 as of its most recent filing with the Securities & Exchange Commission.
COPYRIGHT VIOLATION NOTICE: This piece was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://www.chaffeybreeze.com/2018/01/04/palatin-technologies-ptn-shares-gap-up-to-0-84.html.
Palatin Technologies Company Profile
Palatin Technologies, Inc is a biopharmaceutical company. The Company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems.
Receive News & Ratings for Palatin Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies and related companies with MarketBeat.com's FREE daily email newsletter.